Founded with a mission to revolutionize wound care, Omeza specializes in omega-3 rich treatments for chronic wounds and venous leg ulcers. The company aims to improve patient outcomes through innovative, multimodal therapies that address all phases of wound healing. Their flagship product, OCM™, is a unique drug-device combination designed to deliver comprehensive care. Omeza primarily serves healthcare professionals and patients in the hospital and healthcare sectors.
Notable affiliations include partnerships with leading healthcare providers and researchers. Omeza has secured investment from prominent venture capital firms focused on healthcare innovation. Key achievements include the development and successful market introduction of OCM™, which has been well-received by both medical professionals and patients for its efficacy. Overall, Omeza's impact lies in its ability to enhance the quality of wound care, offering advanced solutions that significantly improve healing times and patient comfort.
